Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Document Type
Year range
Biochimica Clinica ; 46(3):S71, 2022.
Article in English | EMBASE | ID: covidwho-2168062


On March 11th, 2020, the World Health Organization (WHO) declared the pandemic status of CoronaVirus Disease-19 (COVID-19) caused by SARS-CoV-2. Viral nucleic acid detection using molecular testing is the gold standard to diagnose SARS-CoV-2 infection. Asymptomatic subjects or with mild symptoms may not be subjected to molecular diagnostic tests with important repercussions on epidemiological estimate. The overall evolution especially of post-pandemic dynamics, will be probably obtained by the detection of immune response. Humoral immune response against the nucleocapsid (N) protein is related to SARS-CoV-2 infection. The detection of these antibodies could discriminate cases with from cases without history of COVID-19 for a more accurate evaluation of population exposed to SARSCoV-2. In this retrospective study, we evaluated four subclasses of SARS-CoV-2 IgG (anti-S1, anti-S2, anti-RBD, anti-N) in n.200 blood samples (February-March 2022) of health workers of Azienda Sanitaria Provinciale (ASP) di Ragusa, already vaccinated against Covid-19 in the period February-March 2022. A statistically significant association between SARS-CoV-2 infection and seropositivity to anti-N IgG (p-value <0.0001) was found. In order to evaluate the SARS-CoV-2 anti-N antibodies titer trend, the cases with a positive history for COVID-19 were classified as follows: cases with infection within three months and cases with infection after three months from serological test.No statistically association (p-value= 0.075) was found between seropositivity to anti-N IgG and SARS-CoV-2 infection within and after three months. We observed that approximately 30% of cases with a history for COVID-19 was seronegative for anti-N IgG within three months from infection.In post-pandemic period the evaluation of anti-N IgG in a time interval of less than three months could identify asymptomatic population exposed to SARS-CoV-2. Although our findings should be validated with a larger cohort, these results suggest that anti-N IgG might be used as a marker of early infection and assure a more accurate epidemiological estimate.

European Journal of Neurology ; 28(SUPPL 1):159, 2021.
Article in English | EMBASE | ID: covidwho-1307714


Background and aims: Mounting data has been published as to the impact of SARS-CoV-2 on cerebrovascular events, particularly on ischemic strokes. Our study addresses the clinical course of patients with cerebral haemorrhage and simultaneous SARS-CoV-2 infection, paying particular attention to both SARS-CoV-2 positive and negative patients hospitalized during the pandemic. Methods: The Italian Society of Hospital Neurosciences (SNO) promoted a multicentre, retrospective, observational study (SNO-COVID-19), involving 20 Neurology Units in Northern Italy. Data were collected on patients consecutively admitted to neurological departments, from March 1st to April 30th with cerebrovascular diseases, occurring either at home or during hospitalization for other causes. Results: 949 patients were enrolled (average age 73.4 years;52.7% males);135 patients had haemorrhagic stroke and 127 (13.4%) had a primary ICH. Only 16 patients with ICH (12.6%) had laboratory confirmed SARS-CoV-2 infection, clinically expressed or not. SARS-CoV-2 related pneumonia or respiratory distress, lobar location and previous antiplatelet or anticoagulant treatment were the only factors significantly associated with increased mortality in ICH. SARS-CoV-2 infection, regardless of respiratory involvement, led to a nonsignificantly increased risk of in-hospital death. Conclusion: Our study confirms that age, ICH location and previous antiplatelet or anticoagulant treatment are predictors of in-hospital death. Unlike ischemic stroke, ICH in SARS-CoV-2 patients led only to a slight increase in mortality, mainly due to respiratory involvement.